Fostemsavir tromethamine - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for fostemsavir tromethamine and what is the scope of patent protection?
Fostemsavir tromethamine
is the generic ingredient in one branded drug marketed by Viiv Hlthcare and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.Fostemsavir tromethamine has thirty-nine patent family members in thirty countries.
One supplier is listed for this compound.
Summary for fostemsavir tromethamine
| International Patents: | 39 |
| US Patents: | 3 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 35 |
| Patent Applications: | 113 |
| What excipients (inactive ingredients) are in fostemsavir tromethamine? | fostemsavir tromethamine excipients list |
| DailyMed Link: | fostemsavir tromethamine at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for fostemsavir tromethamine
Generic Entry Date for fostemsavir tromethamine*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET, EXTENDED RELEASE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for fostemsavir tromethamine
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Viiv Hlthcare | RUKOBIA | fostemsavir tromethamine | TABLET, EXTENDED RELEASE;ORAL | 212950-001 | Jul 2, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Viiv Hlthcare | RUKOBIA | fostemsavir tromethamine | TABLET, EXTENDED RELEASE;ORAL | 212950-001 | Jul 2, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Viiv Hlthcare | RUKOBIA | fostemsavir tromethamine | TABLET, EXTENDED RELEASE;ORAL | 212950-001 | Jul 2, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for fostemsavir tromethamine
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| China | 101941990 | Prodrugs of piperazine and substituted piperidine antiviral agents | ⤷ Try a Trial |
| Peru | 20051151 | PROFARMACOS DE PIPERAZINA Y AGENTES ANTIVIRALES DE PIPERIDINA | ⤷ Try a Trial |
| Japan | 4734318 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
